Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Account Payables
Amounts the company owes suppliers for goods and services received.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 64.5% from a year ago
Account payables stood at $2.07M at the end of Q1 FY2026, down 64.5% from a year earlier and down 48.1% from the prior quarter. Over 3 fiscal years it compounded at -16.2% a year.
Context
- Account payables amounted to 1.7% of total assets at the end of Q1 FY2026, down 2.4 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -64.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 3.98M USD
- Year-over-year change
- -48.5%
- 4-year CAGR
- -15.6%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.98M | -48.5% |
| FY2024 | 2024-12-31 | 7.73M | +68.8% |
| FY2023 | 2023-12-31 | 4.58M | -32.4% |
| FY2022 | 2022-12-31 | 6.78M | -13.6% |
| FY2021 | 2021-12-31 | 7.84M | — |
Account Payables vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -64.5% is the lowest of 10, against a peer median of -9.6%.
- Account payables amounts to 1.7% of total assets for PRLD, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.45B USD | +110780.3% | -21.2% | 0.7% | |
| Dec 2025 | €26.01M EUR | -20.9% | +10.3% | 10.4% | |
| Mar 2026 | $6.31M USD | +13.5% | +15.4% | 6.3% | |
| Mar 2026 | $4.99M USD | +75.3% | +15.3% | 7.8% | |
| Mar 2026 | $4.36M USD | -8.3% | -31.3% | 1.4% | |
| Mar 2026 | $3.5M USD | -9.6% | +71.5% | 2.4% | |
| Mar 2026 | $3.32M USD | -18.5% | -7.6% | 1.5% | |
| Mar 2026 | $2.07M USD | -64.5% | -16.2% | 1.7% | |
| Mar 2026 | $1.91M USD | -62.2% | -28.0% | 1.4% | |
| Mar 2026 | $356K USD | -47.7% | -63.8% | 0.4% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding PRLD) | — | -9.6% | -7.6% | 1.5% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31.83M | 30.61M | 25.29M | 12.47M | 35.26M |
| Short-term Investments | 259.41M | 171.12M | 207.64M | 121.14M | 67.96M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.65M | 2.65M | 2.28M | 2.48M |
| Total Current Assets | 295.12M | 204.38M | 235.59M | 135.9M | 105.69M |
| Property, Plant & Equipment (Net) | 5.64M | 6.7M | 37.74M | 35.47M | 32.28M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.35M | 9.42M | 4.34M | 4.15M | 3.35M |
| Total Non-current Assets | 9.98M | 16.12M | 42.08M | 39.62M | 35.62M |
| Total Assets | 305.1M | 220.5M | 277.67M | 175.52M | 141.32M |
| Account Payables | 7.84M | 6.78M | 4.58M | 7.73M | 3.98M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 33.73M |
| Other Current Liabilities | 5.01M | 6.21M | 6.61M | 9.79M | 5.4M |
| Total Current Liabilities | 19.2M | 21.7M | 21.83M | 25.64M | 52.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 1.8M |
| Other Non-current Liabilities | 0 | 3.36M | 3.34M | 3.09M | 2.84M |
| Total Non-current Liabilities | 0 | 3.36M | 18.75M | 18.42M | 19.68M |
| Total Liabilities | 19.2M | 25.06M | 40.58M | 44.06M | 72.68M |
| Common Stock | 5K | 5K | 5K | 5K | 5K |
| Retained Earnings | (219.12M) | (334.56M) | (456.39M) | (583.56M) | (683.06M) |
| Accumulated OCI | (711K) | (1.69M) | 223K | 35K | 8K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 285.9M | 195.44M | 237.09M | 131.46M | 68.64M |
| Total Debt | 1.74M | 1.83M | 16.89M | 18.03M | 17.79M |
| Net Debt | (30.09M) | (28.77M) | (8.4M) | 5.55M | (17.47M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.